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Introduction
Disorders of  human male reproductive health that manifest at birth (cryptorchidism, hypospadias) or 
in young adulthood (low sperm count, testicular germ cell cancer [TGCC], primary hypogonadism) are 
remarkably common, and some, at least, are increasing in incidence (1–3). In Northern Europe, about 1 in 
6 young men will have one or more of  these disorders (3–5). It has been hypothesized that these disorders 
may comprise a testicular dysgenesis syndrome (TDS) with a common origin in fetal life (3, 6, 7), perhaps 
related to subtle deficiencies in fetal androgen (testosterone) production or action (8). The original motiva-
tion for this hypothesis was the discovery that TGCC that occurs in young men arises because of  a failure 
of  fetal germ cells (gonocytes) to differentiate normally (3, 6, 9, 10) and that risk of  TGCC is related to 
other TDS disorders (3, 6).
While the fetal origin of  cryptorchidism and hypospadias is self-evident, it is not an obvious explana-
tion for adult-onset disorders, such as low sperm count and hypogonadism, which involve processes and 
cells that do not emerge until after puberty. Moreover, testing whether such adult-onset disorders originate 
in fetal life is challenging in humans, as it requires “looking back in time” over 20 or more years (2, 11). 
Consequently, the TDS hypothesis remains largely untested and unproven (12, 13), although circumstantial 
supporting evidence from clinical studies has grown progressively (1, 3, 5, 14, 15). If  the TDS hypothesis 
was proved correct, it would refocus research effort in humans toward identifying causal factors acting via 
the pregnant mother that might be preventable.
The TDS hypothesis focused on “dysgenesis,” because adult men with TDS disorders often exhibit 
focal morphological abnormalities of  the testis, such as abnormal-shaped seminiferous tubules, Leydig cell 
The testicular dysgenesis syndrome (TDS) hypothesis, which proposes that common reproductive 
disorders of newborn and adult human males may have a common fetal origin, is largely untested. 
We tested this hypothesis using a rat model involving gestational exposure to dibutyl phthalate 
(DBP), which suppresses testosterone production by the fetal testis. We evaluated if induction 
of TDS via testosterone suppression is restricted to the “masculinization programming window” 
(MPW), as indicated by reduction in anogenital distance (AGD). We show that DBP suppresses fetal 
testosterone equally during and after the MPW, but only DBP exposure in the MPW causes reduced 
AGD, focal testicular dysgenesis, and TDS disorders (cryptorchidism, hypospadias, reduced adult 
testis size, and compensated adult Leydig cell failure). Focal testicular dysgenesis, reduced size of 
adult male reproductive organs, and TDS disorders and their severity were all strongly associated 
with reduced AGD. We related our findings to human TDS cases by demonstrating similar focal 
dysgenetic changes in testes of men with preinvasive germ cell neoplasia (GCNIS) and in testes 
of DBP-MPW animals. If our results are translatable to humans, they suggest that identification 
of potential causes of human TDS disorders should focus on exposures during a human MPW 
equivalent, especially if negatively associated with offspring AGD.
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nodules, or Sertoli cell–only (SCO) tubules, in which the Sertoli cells are often visibly undifferentiated (3, 
7, 16–18). This was interpreted as evidence for abnormal early development of  the testis, which then led, 
secondarily, to impaired functions of  fetal somatic or germ cells, culminating in TDS disorders (3, 6). In 
this regard, it is important to highlight that, while gross impairment of  early testis development can result 
in overt dysgenesis and resulting downstream effects (18, 19), the primary focus of  the TDS hypothesis 
is on men in whom the dysgenetic changes are focal, often in an otherwise largely normal testis (16–18). 
However, it is impossible to identify that such focal dysgenesis in testes of  adult men originates from mal-
development of  the fetal testis.
Understanding of  the fetal origins of  male reproductive disorders in laboratory animals changed dra-
matically in 2008 with the discovery of  the “masculinization programming window” (MPW) (20). The 
MPW refers to the window of  time during fetal development in which androgen actions program later 
development of  all male reproductive organs, including their ultimate adult size and function (20–22). A 
vital finding was that anogenital distance (AGD), which is normally about twice as long in rodent males 
as in females, was also programmed by androgen action within the MPW (20, 23). Hence, AGD could be 
measured at any postnatal age in rats and used to retrospectively decipher the level of  fetal androgen expo-
sure during the MPW (11, 21). In human males, AGD shows similar male-female differences as in rats (11, 
24–26), and lower AGD has been related to the occurrence of  TDS disorders evident at birth (27–33) and, 
in a majority of  studies, to lower sperm counts (34–37) and hormone levels (38, 39) in adult men, similar 
to rats (reviewed in ref. 11). Such findings are consistent with the TDS hypothesis and suggest, but do not 
prove, that TDS disorders in men may originate within a MPW.
Because of  inherent limitations in human studies, the TDS hypothesis can realistically only be tested 
using an animal model approach. Identification of  the MPW in rodents was based on use of  the androgen 
receptor antagonist flutamide (20), but in humans TDS is considered to result from maldevelopment and 
consequent malfunction of  the fetal testis (3, 6), so that a model with such changes was needed. Our earlier 
studies suggested that exposure of  pregnant rats to the environmental chemical dibutyl phthalate (DBP) 
might be a potential model for TDS in humans, as the testis differentiates normally after DBP exposure 
(40), but this treatment induces focal dysgenesis (40–42) and reduces fetal testis testosterone levels via 
effects on steroidogenic gene expression (43–45), which then causes TDS disorders (41, 42, 46). However, 
such studies were undertaken before the importance of  the MPW had been identified. Thus, the hypothesis 
we tested in the present study had two aims: first, to assess if  DBP-induced TDS disorders, that manifest at 
birth or in adulthood, are only inducible by DBP exposure (and associated androgen deficiency) during the 
MPW and second, to establish what relationship these changes had to focal testicular dysgenetic changes, 
comparable to those evident in human TDS cases. Our results show that only DBP exposure during the 
MPW results in TDS disorders and that this is intrinsically linked to occurrence of  focal dysgenesis, even 
when DBP exposure commenced after normal testis differentiation and early development. Our findings 
also reaffirm (20) that AGD provides a specific, lifelong “readout” of  the level of  androgen exposure during 
the MPW. We suggest that these findings provide robust animal model validation of  the TDS hypothesis 
and, assuming their translation to the human, they have fundamental health and research implications.
Results
Comparative fetal effects of  DBP exposure (750 mg/kg/d) during the MPW (E15.5–E18.5) or immediately after 
this period (late window; E19.5–E20.5). Most morphological signs of  androgen-driven masculinization 
emerge in the rat fetus during the period from E18.5 to E21.5 after the MPW, but these changes are 
actually induced (programmed) by androgen exposure in the prior MPW (20). Hence, we used differ-
ential DBP exposure during the MPW or in the period immediately afterward (late window [LW]) to 
evaluate the relative importance of  DBP-induced differences in androgen exposure in the MPW and 
LW in the origin of  TDS disorders.
DBP exposure during either the MPW or LW caused comparable suppression (47%–48%) of  intrates-
ticular testosterone (ITT) in male fetuses when measured 48 hours after the commencement of  daily DBP 
treatment (Figure 1A). In fetuses exposed to DBP only during the MPW, ITT levels had recovered to near 
normal by E21.5 (Figure 1A). Despite the similar magnitude of  DBP-induced suppression of  ITT during 
the MPW and the LW, only male rat fetuses exposed to DBP during the MPW exhibited a significant 
reduction in AGD at E21.5 (Figure 1B). At E17.5 (during the MPW), the only detectable morphological 
effect of  DBP exposure was central aggregation of  fetal Leydig cells in comparison with controls (compare 
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Figure 1C and Figure 1D); in earlier studies, we showed that DBP treatment does not alter fetal Leydig cell 
number (47). Fetal Leydig cell aggregation induced by DBP exposure during the MPW was still evident at 
E21.5 (Figure 1F) but was not present in controls (Figure 1E) or in DBP-treated animals in the LW (DBP-
LW) (Figure 1G). At E21.5, but not at E17.5 (during DBP exposure; Figure 2, A and B), an additional 
change, which was confined to the DBP-MPW–exposed group, manifested as the appearance of  numerous 
ectopic Sertoli cells in approximately 80% of  fetuses, scattered among the aggregated fetal Leydig cells 
(Figure 2, D and F). In contrast, ectopic Sertoli cell number in the DBP-LW group remained at background 
levels, comparable to controls (Figure 2, C, E, and F). Therefore, DBP induction of  focal dysgenesis (Ley-
dig cell aggregation, ectopic Sertoli cells) in the fetal testis requires DBP exposure during the MPW and is 
not inducible by DBP-LW exposure.
Reproductive organ weights of  adult male rats following DBP-induced androgen deficiency in fetal life. Rats in the 
DBP-LW group exhibited a normal adult phenotype, indistinguishable from controls with respect to testis 
weight, penis length, prostate weight, and AGD (Figure 3, A–D). In contrast, adult males from the DBP-
MPW group exhibited significant reductions in all of  these parameters compared with controls (Figure 3, 
A–D). We also evaluated whether exposure of  rats to DBP from E13.5 to E21.5 (full window [FW]), which 
encompassed the 2 days before the MPW (when testis differentiation occurs), the MPW, and the LW, induced 
a more severe reproductive phenotype than DBP exposure just during the MPW. Unexpectedly, we found 
evidence for the opposite, as the adverse reproductive changes in adult rats from the DBP-MPW group were 
consistently more marked than in those from the DBP-FW group, although this difference was only statis-
tically significant for AGD and penis length (Figure 3, A–D). Using AGD as a “readout” of  the level of  
androgen exposure during the MPW (19), it was evident that testis size (Figure 3E), penis length (Figure 3F), 
and prostate weight (Figure 3G) were all strongly correlated with AGD when data from all adult males in this 
study were analyzed together.
Occurrence of  cryptorchidism and hypospadias in adult rats following DBP-induced androgen deficiency in fetal 
life. Rats from the DBP-MPW group exhibited a high incidence of  cryptorchidism (64%) and hypospadias 
(52%), whereas no cases of  these disorders occurred in controls and only 1 male in the DBP-LW group had a 
mild glanular hypospadias (Figure 4A). The induced cryptorchidism was bilateral in 69.7% of  DBP-MPW–
exposed rats and unilateral in the remainder. Similarly, in the DBP-MPW group, the induced hypospadias 
was severe (perineal) in 73.1% of  rats with this disorder and mild to moderate in the remainder; in severe 
cases, there was also marked chordee.
When adult rats in the study were categorized according to the absence or presence of  a genital abnor-
mality (and, if  present, its severity), irrespective of  their treatment group, it was evident that the more 
severe the genital abnormality, the smaller the AGD (Figure 4B). Thus, animals with bilateral cryptorchi-
dism had significantly shorter (P < 0.001) AGD than did animals with unilateral cryptorchidism, and the 
latter had significantly shorter (P < 0.001) AGD than did animals with bilateral scrotal testes (Figure 4B). 
A similar trend was evident for grades of  hypospadias. Animals with severe hypospadias had significantly 
shorter (P < 0.001) AGD than either rats without hypospadias or rats with mild or moderate hypospadias, 
with AGD in the latter group being significantly shorter (P < 0.05) than in animals with a normally posi-
tioned penile urethral opening (Figure 4B).
Effect of  DBP-induced androgen deficiency in fetal life on adult Leydig cell function. We have shown previously 
that deficiency in fetal androgen action in rats/mice results in “compensated Leydig cell failure” in adult-
hood (48), so we evaluated if  such effects were also connected to the MPW. Exposure to DBP in either 
the MPW or LW did not alter mean plasma levels of  testosterone in adulthood (Figure 5A). However, 
rats from the DBP-MPW group exhibited marked elevation of  plasma luteinizing hormone (LH) levels 
in comparison with controls (Figure 5B) and, thus, had a distorted LH/log testosterone ratio (Figure 5C) 
indicative of  compensated Leydig cell failure (5, 48, 49). DBP-MPW–induced compensated Leydig cell 
failure was evident in animals with scrotal or cryptorchid testes, although the magnitude of  the effect was 
significantly greater for animals with cryptorchid testes (Figure 5C). In contrast, DBP-LW rats had normal 
LH levels and did not exhibit compensated Leydig cell failure (Figure 5, B and C). Consistent with the 
hypothesis that compensated Leydig cell failure originates from DBP-induced testosterone suppression in 
the MPW, a significant negative correlation was found between AGD and the LH/log testosterone ratio 
when data for all animals in the study were analyzed together (Figure 5D). A similar negative relationship 
was found between the LH/log testosterone ratio and average testis weight, which can be equated to the 
number of  germ cells/sperm production (Figure 5E).
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Dysgenetic features in the adult testes of  DBP-exposed rats. DBP exposure in utero induces histologi-
cal changes in the testis that are evident in adulthood as focal dysgenetic areas (41, 42, 50) (Supple-
mental Figure 1; supplemental material available online with this article; https://doi.org/10.1172/jci.
insight.91204DS1). It has not been evaluated previously whether DBP-induced dysgenesis is confined to 
animals exposed specifically during the MPW. Therefore, we systematically evaluated the testes of  repre-
sentative adult rats from the control, DBP-MPW, and DBP-LW groups to evaluate 4 specific dysgenetic 
features (see Figure 6 for examples), namely the occurrence of  (a) focal dysgenetic areas (focal groups 
of  malformed seminiferous tubules), (b) seminiferous tubules with a subnormal germ cell complement 
(impaired spermatogenesis), (b) SCO tubules, and (d) tubules with intratubular Leydig cells. For the DBP-
MPW group, we analyzed 6 rats with bilateral or unilateral cryptorchidism and 13 rats with noncryptor-
chid testes, which included testes that were normally scrotal (n = 6) as well as those that were labeled as 
inguinal (n = 7); the latter were defined at necropsy as testes that were scrotal/high scrotal, but which had 
Figure 1. Effect of fetal exposure of rats to dibutyl phthalate during the masculinization programming window or 
immediately afterward (late window) on intratesticular testosterone, anogenital distance, and gross testis morpholo-
gy at E17.5 and E21.5. Intratesticular testosterone (A), anogenital distance (B), and gross testis morphology (C–G) at E17.5 
and E21.5. Note that E17.5 is during the MPW, E21.5 is at the end of the LW. (A and B) Values are mean ± SEM, with anal-
ysis by 2-tailed Student’s t test or ANOVA with Bonferroni correction (**P < 0.01, ***P < 0.001, compared with respective 
control). (C–G) Sections were triple immunostained for SOX9 (red; Sertoli cells), 3β-HSD (green; Leydig cells), and smooth 
muscle actin (blue). Asterisks indicate abnormal aggregation of fetal Leydig cells (green). Scale bars: 200 μM. DBP, dibutyl 
phthalate; MPW, masculinization programming window; LW, late window; AGD, anogenital distance.
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an absent or abnormally elongated gubernacular ligament, meaning that the testis could not be normally 
anchored in the scrotum. This phenotypic selection was reflective of  the DBP-MPW treatment group as 
a whole and enabled us to evaluate whether focal dysgenesis was related to testis position/phenotype. 
All testes from control and DBP-LW animals were scrotal. To facilitate identification of  focal dysgenetic 
features, whole testis cross sections (2 per rat from different testis areas) were immunostained for VASA 
(specific to germ cells), 3β-HSD (specific to Leydig cells), or smooth muscle actin (SMA; expressed in 
peritubular myoid cells and blood vessels) to delineate seminiferous tubule boundaries.
Adult rats from the DBP-LW group (n = 6) showed no focal dysgenetic features in their testes and were 
thus comparable to controls (Figure 6, A, C, and E). In contrast, rats from the DBP-MPW group exhibited 
frequent occurrence of one or more focal dysgenetic features (Figure 6). Focal dysgenesis was most common in 
cryptorchid testes, 100% of which exhibited two or more focal dysgenetic features, whereas only approximately 
70% of noncryptorchid testes exhibited one or more focal dysgenetic features. The least commonly observed 
focal dysgenetic feature was intratubular Leydig cells (Supplemental Figure 2). Overall, focal dysgenesis within 
the testis was more common in animals with a genital abnormality (i.e., cryptorchidism) (Figure 6).
Dysgenetic features in the testes of  human TDS cases. Testicular dysgenesis encompasses a spectrum rang-
ing from testes that are completely malformed (probably accompanied by lack of  virilization) to testes in 
which only patchy/focal areas of  the testis may be abnormal (focal dysgenesis) and in which the affected 
men are normally virilized and devoid of  other nonreproductive pathologies (18, 51). An example of  the 
latter is young men with preinvasive TGCC, i.e., intratubular germ cell neoplasia in situ (GCNIS; refs. 9, 
Figure 2. Dibutyl phthalate–induced 
dysgenesis of the fetal testis at E17.5 
(Leydig cell aggregation) or E21.5 
(increased numbers of ectopic Sertoli 
cells) occurs after exposure in the mas-
culinization programming window but 
not the late window. Note that E17.5 
is during the MPW, E21.5 is at the end 
of the LW. (A–E) Sections were triple 
immunostained for SOX9 (red; Sertoli 
cells), 3β-HSD (green; Leydig cells), and 
smooth muscle actin (SMA) (blue; per-
itubular myoid cells). Asterisks indicate 
normal seminiferous cords, and white 
arrows show examples of ectopic Sertoli 
cells, numbers of which were increased 
selectively at E21.5 (D and F) but not 
at E17.5 (B and F) in the DBP-MPW 
group; there was no change in ectopic 
Sertoli cells or fetal Leydig cell aggre-
gation at E21.5 in the DBP-LW group 
(F). Scale bars: 20 μM. (F) Values are 
mean ± SEM, with analysis by 2-tailed 
Student’s t test (E17.5) or ANOVA with 
Bonferroni correction (E21.5) (***P < 
0.001, in comparison to E21.5 control). 
DBP, dibutyl phthalate; dys, dysgenesis; 
MPW, masculinization programming 
window; LW, late window.
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10, 18), who constitute the definitive TDS case (6). We specifically selected 10 such samples from a tissue 
archive on the basis of  the presence of  GCNIS (but no TGCC); their mean age was 29.6 years (range, 17–44 
years). Although we cannot definitively exclude that these men might have had another condition that could 
affect testicular histology, to reduce the chances of  such confounding, we used as one of  our control groups 
GCNIS-free (“normal”) biopsies from the contralateral testes of  men who had been diagnosed with TGCC 
(n = 8), who might be expected to be at equivalent risk of  having an unrelated condition affecting their testes 
(52). These biopsies had been taken to establish if  GCNIS was present and proved to be negative based on 
routine histological and immunohistochemical analyses; the mean age of  the men providing these biopsies 
was 38.8 years (range 33–50 years). As approximately 15% of  such testes may still harbor dysgenetic features 
(16), a second group of  controls (n = 4) was examined, these being men having a mean age of  40 years (range 
33–52 years) in whom one testis had been removed because of  chronic pain and in which no histological 
evidence for testicular abnormality was found. As no significant differences were found between these two 
control groups, they were pooled for comparison with the GCNIS preinvasive TGCC group. We evaluated 
Figure 3. Dibutyl phthalate exposure in the masculinization programming window, but not the late window, reduces anogenital distance and 
reproductive organ size in adulthood. (A) Anogenital distance and (B–D) reproductive organ size in adulthood in the different treatment groups. Data 
are also shown for rats exposed to DBP during the FW (E13.5–E21.5), which encompasses the MPW and LW. Values are mean ± SEM, with analysis by 
ANOVA with Bonferroni correction (***P < 0.001, in comparison to respective control). (E–G) Linear correlation between anogenital distance and adult 
reproductive organ size for all animals from the treatment groups in A–D. DBP, dibutyl phthalate; FW, full window; MPW, masculinization program-
ming window; LW, late window.
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the occurrence of  focal dysgenesis in these 3 groups of  men using the same identification criteria as that used 
in the rat DBP studies reported above to enable comparison of  human and rat TDS cases.
In control men, no focal dysgenetic areas (abnormally formed tubules) were found (Figure 7A), but 
3 of  12 men had a few scattered seminiferous tubules (3.0% ± 0.2%; mean ± SEM; n = 3) classified as 
being SCO or having a subnormal germ cell complement (Figure 7, D and G). In contrast, all 10 men 
with preinvasive TGCC exhibited one or more testicular dysgenetic features. Focal dysgenetic areas were 
found in 6 of  the 10 men with preinvasive TGCC (Figure 7, A–C). However, the most common features 
were SCO tubules and tubules with abnormal spermatogenesis (Figure 7, D–I), which affected 43.2% ± 
6.8% (mean ± SEM, n = 10) of  all tubules evaluated; this was notably more extensive than in the 3 control 
men who exhibited such features (P = 0.007; Mann-Whitney test). Intratubular Leydig (CYP11a1-immu-
nopositive) cells were not identified in any of  the 10 preinvasive TGCC samples or in controls. We decided 
not to extend our quantitative analysis of  dysgenetic features to men with low sperm counts because 
we did not have any definitive means of  proving that any abnormalities found could be attributed to 
Figure 4. Dibutyl phthalate exposure in the masculinization programming window, but not the late window, increases incidence of hypospadias and 
cryptorchidism in adulthood. (A) The relationship between genital phenotype and DBP treatment window. (B) The relationship between genital pheno-
type and AGD for all rats from the treatment groups in A. Data in A were analyzed using Fisher’s exact test with Bonferroni correction (***P < 0.001, in 
comparison to respective control group); data in B (mean ± SEM) were analyzed by ANOVA with Bonferroni correction (*P < 0.05, ***P < 0.001, in compari-
son to rats with a phenotypically normal penis [bottom left] or with bilateral scrotal testes [bottom right]). DBP, dibutyl phthalate; MPW, masculinization 
programming window; LW, late window; AGD, anogenital distance.
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“dysgenetic” events in fetal life. However, dysgenetic features comparable to those shown in Figure 7 in 
men with GCNIS were evident in many biopsies from men with low sperm counts, and one example, 
which includes an extensive focal dysgenetic area, is illustrated in Supplemental Figure 3.
Fetal origin of  focal dysgenetic areas in DBP-exposed rats. Focal dysgenetic features in the adult testis, whether 
in human cases or in DBP-exposed rats, cannot be proved to originate in fetal life, as there is no direct way of  
following or tracing them over time. Therefore, the approach we took was based on the hypothesis that the 
focal areas of malformed seminiferous tubules (dysgenetic areas; Figure 6, A and B) in testes of adult rats (DBP 
exposed) derived from the “focal dysgenetic regions” of aggregated fetal Leydig cells and ectopic Sertoli cells 
that were induced in fetal life by DBP-MPW exposure (Figures 1 and 2). If  this was correct, focal dysgenetic 
features should be detectable after birth and during the prepubertal period in testes of DBP-MPW–exposed ani-
mals. Accordingly, we examined the testes of DBP-MPW–exposed rats at postnatal days (Pnd) 4, 10, 15, and 
25 and immunostained for SMA (to delineate seminiferous tubules) and 3β-HSD (to identify Leydig cells). As 
illustrated in Figures 6 and 8, 53%–83% of DBP-MPW–exposed rats had one or more dysgenetic foci within 
their testes at all ages examined, although the size and shape of these regions varied considerably. At Pnd 4, 
focal dysgenetic areas appeared similar to those in the E21.5 fetal testis (Figure 8A) with aggregated Leydig 
cells (compare Figure 8, A–C). However, unlike the fetal testes in which isolated ectopic Sertoli cells were 
present (see Figure 2), in the Pnd 4 testes of DBP-MPW–exposed animals, some degree of cord formation 
appeared to be taking place within the focal dysgenetic areas, as evidenced by appearance of SMA-immu-
nopositive peritubular myoid cells (Figure 8, B and C); isolated germ cells were also evident in these regions 
(Figure 8C). The formation of foci of abnormally shaped “anastomotic” seminiferous cords/tubules, some of  
which harbored intratubular 3β-HSD–immunopositive (Leydig) cells (Figure 8F, inset; Supplemental Figure 2), 
was more prominent at later ages (Pnd 10–25; Figure 8, D–F). These focal dysgenetic areas were comparable 
to those seen in adulthood in DBP-MPW–exposed animals (Figure 6A and Supplemental Figure 1). Focal dys-
genetic areas were never observed in the testes of comparably aged control or DBP-LW rats (data not shown).
Figure 5. Dibutyl phthalate exposure in the masculinization programming window, but not the late window, results in compensated Leydig cell failure 
in adulthood. Note that blood testosterone levels are not different between groups (A), but DBP-MPW rats require significantly higher LH levels (B) to 
maintain this, resulting in an increase in the LH/log testosterone ratio (C) specifically in the DBP-MPW group; this was evident for rats with scrotal or 
cryptorchid testes but was more marked for the latter (C). Compensated Leydig cell failure was inversely correlated with anogenital distance (D) and average 
testis weight (E). (A–C) Values are mean ± SEM, with analysis by ANOVA with Bonferroni correction (**P < 0.01, ***P < 0.001, in comparison to respective 
control). (D and E) Data were analyzed by linear regression. DBP, dibutyl phthalate; MPW, masculinization programming window; LW, late window.
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Figure 6. Dibutyl phthalate exposure in the masculinization programming window, but not the late window, increases incidence of focal dysgenesis in 
the adult testis. Incidence data (left) and examples of the phenotype (right) are shown for focal dysgenetic areas (A and B; highlighted by yellow dashed 
border in B; brown staining indicates SMA to delineate peritubular myoid cells and blue staining indicates 3β-HSD to identify Leydig cells), tubules with 
incomplete spermatogenesis (C and D; highlighted by asterisk in D; brown staining indicates DAZL to identify germ cells), and Sertoli cell–only (SCO) 
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Interrelationship between focal dysgenetic areas and AGD (as an indicator of  fetal androgen exposure in the MPW) 
in rats. To provide insight into the relationship between AGD and focal testicular dysgenesis, we evaluated 
the correlation between AGD and the number of  ectopic Sertoli cells per testis cross section in the fetal 
E21.5 testis (Figure 2, D and F) or focal dysgenetic areas in the adult testis (Figure 6A). For the latter anal-
ysis, the total cross-sectional area of  focal dysgenetic regions was measured and expressed as a percentage 
of  the total testis area, based on analysis of  two complete cross sections from different regions of  the testis 
of  each adult rat. The results showed a significant negative correlation between AGD and focal dysgenesis, 
irrespective of  whether it was measured at E21.5 or in adulthood (Figure 9).
Discussion
The present studies tested three interrelated hypotheses: first, that the hypothesis concerning human TDS can 
be verified in an experimental animal model; second, that TDS disorders arise as a consequence of  andro-
gen deficiency within the previously identified MPW (ref. 20); and third, that TDS disorders and androgen 
deficiency (in the MPW) are linked to occurrence of  focal dysgenesis. Our results provide robust support for 
the hypothesis that TDS disorders originate in fetal life and demonstrate that these disorders are only induc-
ible by DBP-induced androgen deficiency in rats when the deficiency occurs specifically within the MPW. 
DBP induction of  comparable fetal androgen deficiency after the MPW does not induce TDS disorders, 
and neither does more prolonged DBP-induced androgen suppression before, during, and after the MPW 
(DBP-FW treatment regimen) induce any greater incidence of  TDS disorders than treatment just within the 
MPW; if  anything the opposite is the case. We also show that DBP-induced focal dysgenesis, comparable to 
that found in the testes of  some men with TDS disorders, is closely linked in rats to TDS disorders and to the 
MPW. Therefore, our results provide insights into the mechanistic basis and associations of  TDS disorders. 
They also reaffirm the utility of  AGD as a lifelong readout of  androgen exposure within the MPW (20), with 
certain minor caveats (11, 53), and as an indicator of  risk of  TDS disorders and focal dysgenesis.
The TDS hypothesis has focused attention and research effort on reproductive disorders in newborn 
boys and young men. As some of  these disorders are very common and/or may be increasing in incidence 
(1, 3, 7), concerns have focused on what might cause this high incidence. If  the TDS hypothesis is correct, 
concern would be focused on factors acting during pregnancy (3, 7). The TDS hypothesis cannot be tested 
by studies in man, because it is not possible to evaluate androgen exposure and fetal testis development and 
relate this to subsequent disorders evident at birth or to adult-onset disorders, such as low sperm count. The 
only realistic possibility was to evaluate the TDS hypothesis in an animal model, as in the present studies, 
and then to assess the relevance of  the model findings to man and their fit with the original TDS hypothesis.
Two key findings from the present studies are (a) demonstration of  the close interrelationship between 
DBP-induced focal (histological) dysgenesis in the adult rat testis and occurrence of  TDS disorders, such 
as cryptorchidism, and (b) that a similar interrelationship is evident in fetal life between DBP-induced focal 
testicular dysgenesis and the degree of  suppression of  androgen exposure in the MPW, as indicated by AGD. 
The precise basis for such a link is not obvious because there is no evidence that intratesticular androgen defi-
ciency causes testicular morphological changes, especially when the critical period (MPW) is after completion 
of  testis differentiation and seminiferous cord formation (Figure 10). We suggest that “focal dysgenesis,” 
manifesting as abnormal organization/distribution of  testicular somatic cells (e.g., of  fetal Leydig and Sertoli 
cells as shown presently), leads to deficiencies in somatic cell function (e.g., fetal Leydig cell steroidogenesis 
and immaturity/dysfunction of  Sertoli cells that fail to properly support germ cell development), which in 
turn leads to reduced reproductive organ size and AGD as well as increased incidence of  TDS disorders 
(Figure 10). Hence, the close interrelationship between focal testicular dysgenesis and occurrence/severity of  
TDS disorders is probably not because one causes the other, but because both share a common origin/cause 
(Figure 10), consistent with the original TDS hypothesis (6). This is supported by the fact that focal dysgenesis 
is inversely correlated with AGD in fetal life (this study and ref. 40) and adulthood (this study).
Our results provide both indirect and direct evidence to support the translatability of  the present animal 
model results to humans. Indirect support comes from our demonstration of  the robust interrelationship in 
rats between reduced AGD and occurrence of  TDS disorders as well as focal testicular dysgenesis; AGD 
tubules (E and F; brown staining indicates DAZL to identify germ cells). Scale bars: 200 μM. Note that results for the DBP-MPW group are categorized 
according to the testicular phenotype. Analysis was by Fisher’s exact test with Bonferroni correction. DBP, dibutyl phthalate; MPW, masculinization pro-
gramming window; LW, late window.
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provides a highly specific readout of  androgen exposure within the MPW in rats (this study and ref. 20). 
As there is already a substantial body of  similar association data in human males (Table 1), it is reasonable 
to propose that an MPW exists in humans, so that studies to identify potential causes of  TDS disorders 
should focus on the presumptive MPW during fetal development. The timing and duration of  the MPW in 
humans is unknown but may be within 8 to 14 weeks’ gestation, based on fetal AGD measurements (20). 
Thus, there is a significant male-female difference in AGD by 11–13 weeks’ gestation (54), which is fully 
developed by 17–20 weeks (26, 54). Moreover, fetal exposure to painkillers, which has been shown to sup-
press testosterone production by the fetal human testis (55), is associated with reduced AGD in boys (56, 
57), and this may be restricted to exposures during 8–14 weeks’ gestation (56).
To provide more direct evidence for human relevance of  the present experimental rat studies, we 
showed that similar focal dysgenetic features were evident in testis tissue from young adult men with 
GCNIS (preinvasive TGCC) similar to that found in testes from adult rats exposed to DBP during the 
MPW. We chose preinvasive TGCC samples as a human TDS example for two reasons. First, the TDS 
hypothesis was originally based around TGCC and its fetal origins (6). Second, by studying such tissue 
Figure 7. Increased incidence of focal dysgenesis in testes of young men with preinvasive germ cell neoplasia in situ, as exemplars of “human TDS,” in 
comparison to normal controls without germ cell neoplasia in situ. Incidence data (left) and examples of the phenotype (middle and right) are shown for 
focal dysgenetic areas (A–C; highlighted by yellow dashed border in B and C), tubules with abnormal spermatogenesis (D and E; highlighted by asterisks in 
E and F), and Sertoli cell–only (SCO) tubules (G–I). Scale bars: 100 μM. For the photographed images, sections were triple immunostained for SOX9 (brown; 
Sertoli cells), CYP11a1 (red; Leydig cells), and VASA (Blue; germ cells). Tubules containing GCNIS are indicated by pound signs in H. An example of one of the 
normal controls, immunostained for the same 3 proteins, is shown in Supplemental Figure 3. Note that the testis section shown in H and I exhibits some 
nonspecific blue staining in connective tissue/interstitium. Statistical analysis was by Fisher’s exact test. GCNIS, germ cell neoplasia in situ.
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before formation of  an overt tumor, we avoided any potential confounding resulting from the presence 
of  a tumor (9, 18). Although men with low sperm counts/infertility are potentially the largest TDS 
group (2, 3, 6–8) and testes from some such men also show focal dysgenetic features (this study and 
ref. 17), it is not possible to prove that such samples have a fetal origin and are definitive “TDS cases,” 
whereas there is general agreement on the fetal origins of  GCNIS-TGCC (3, 9). No animal model for 
GCNIS-TGCC exists, including the DBP-MPW model. DBP induces fetal germ cell changes, but these 
are not specific to the MPW and are not analogous to how GCNIS is considered to originate (58).
The present findings demonstrate that in rats compensated adult Leydig cell failure is a specific conse-
quence of  DBP-induced androgen deprivation during the MPW, similar to other established TDS disorders, 
such as cryptorchidism and hypospadias (Figure 10 and Table 1). This fits with our finding that AGD, which 
is programmed by androgens during the MPW (20), is negatively correlated with the LH/log testosterone 
ratio, which defines compensated Leydig cell failure. These observations extend our earlier finding that fetal 
androgen deprivation, whether via DBP exposure in rats or transgenesis in mice, results in compensated Ley-
dig cell failure in adulthood via an epigenetic change to the stem/progenitor cells for adult Leydig cells (48).
In human males, compensated adult Leydig cell failure can arise for reasons unconnected to fetal life (59), 
but our experimental rodent findings indicate that, if  associated with a TDS disorder, it might have a fetal ori-
gin (Figure 10), as also suggested by its association with focal dysgenetic changes in the adult rat (this study) 
and human testis (17) and with GCNIS (52). In support of  this, a recent population-based analysis of  >8,000 
young European men showed that those (~16%) with low sperm counts (some cases of  which may arise 
because of  TDS) exhibited compensated Leydig cell failure (5). Moreover, men with idiopathic infertility also 
exhibit compensated Leydig cell failure as a group (49), and some of  these may be examples of  TDS. In young 
men, this could mean that the occurrence of  a low sperm count plus compensated Leydig cell failure might be 
indicative of  TDS; if  this interpretation is correct, such individuals should also have reduced AGD, but this 
has not yet been investigated. Although we did not measure sperm counts in our rat studies, we showed that 
testis weight, which is directly related to daily sperm production (60, 61), was inversely related to compensat-
ed Leydig cell failure. Additionally, our results show that the severity of  DBP-MPW–induced compensated 
Figure 8. Postnatal evolution of focal 
dysgenetic areas in testes of rats exposed 
to dibutyl phthalate in the masculinization 
programming window. Representative images 
from animals at E21.5 (A), postnatal day 4 (Pnd 
4; B and C), Pnd 10 (D), Pnd 15 (E), and Pnd 25 (F) 
are shown after immunofluorescence staining 
for 3β-HSD (dark blue; Leydig cells) and smooth 
muscle actin (brown; peritubular myoid cells and 
blood vessels) to identify focal areas of abnor-
mal seminiferous cords/tubules. Asterisks in A 
and B show focal aggregation of (fetal) Leydig 
cells, which also contain ectopic Sertoli cells (see 
Figure 2). Pnd 4 (B; asterisk = aggregated Leydig 
cells) is the earliest age when focal formation of 
abnormally shaped seminiferous cords/tubules 
becomes evident, but at later ages these are 
fully developed. Focal dysgenetic areas (black 
arrows) varied considerably in shape and size 
and were not found in every animal; an example 
of their appearance in adulthood is shown in 
Supplemental Figure 1 and in Figure 6. The inset 
in F shows a high-magnification view of part of 
the focal dysgenetic area to highlight presence 
of intratubular Leydig cells (arrows). Scale bars: 
200 μM. DBP, dibutyl phthalate; dys, dysgenesis; 
MPW, masculinization programming window.
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Leydig cell failure is increased in rats with a concomitant TDS disorder (i.e., comparison of  rats with descend-
ed versus undescended testes), in keeping with our other findings that the more severe the TDS phenotype, the 
greater the reduction in AGD. More generally, the present experimental studies in rats reinforce the evidence 
that fetal events play a role in determining adult Leydig cell function and testosterone levels in men (14).
Our animal model has limitations. Although some studies have demonstrated an association between 
pregnancy exposure to phthalates such as DBP and reduced AGD in sons (62, 63), more direct studies in 
vitro (64) or by xenografting (65, 66) have shown no effect of  DBP/phthalate exposure on steroidogenesis by 
the fetal human testis. However, our studies were not undertaken to evaluate if  DBP exposure is a cause of  
TDS disorders in humans. We used the DBP-exposed rat simply as a model system in which to test whether 
DBP-induced perturbation of  testis cell organization, and resulting focal dysgenesis and fetal Leydig cell 
Table 1. Comparability of findings in the present rat model of TDS, with observations in human cases classed as TDS and the evidence 
linking them to altered fetal androgen exposure in the masculinization programming window, as indicated by anogenital distance
TDS parameter Human evidence Rat model Refs. for human studies
Cryptorchidism Associated with reduced AGD Associated with reduced AGD  
and focal testicular dysgenesis
27–30
Hypospadias Associated with reduced AGD Associated with reduced AGD  
and focal testicular dysgenesis
28, 30–33, 81
Low sperm count Associated with reduced AGDA Reduced testis size 
(reduced sperm production)  
associated with reduced AGD
34–37
Compensated Leydig  
cell failureB
Associated with low sperm count, infertility, 
and TGCC/GCNIS. Testosterone levels  
positively associated with AGDC
Associated with reduced AGD  
and reduced testis weight. Testosterone  
levels positively associated with AGD
5, 17, 38, 39, 49, 52
TGCC/GCNISD Associated with low sperm count, 
cryptorchidism, focal testicular dysgenesis
TGCC/GCNIS does not occur in  
this/other animal models
3, 6, 16, 18, 51, 52
Note that a minority of studies (those with the A and C footnotes) do not support this view. ATwo studies (39, 80) have shown no significant relationship 
between sperm count and AGD. BAlso termed primary hypogonadism. DGerm cell neoplasia in situ (preinvasive TGCC). DOne study (80) has shown no 
significant relationship between testosterone levels and AGD. TDS, testicular dysgenesis syndrome; AGD, anogenital distance.
Figure 9. Inverse relationship of anogenital distance to focal dysgenesis induced by dibutyl phthalate exposure 
during the masculinization programming window. There is an inverse relationship of AGD to focal dysgenesis in the 
rat testis in fetal life (A; ectopic Sertoli cell number) and in adulthood (B; focal dysgenetic area as percentage of total 
testis cross-sectional area). Data were analyzed by second order polynomial (quadratic) regression, with statistical 
significance evaluated via Spearman correlation. The data sets for A and B correspond to the animals shown in Figure 
2F and Figure 6, respectively. AGD, anogenital distance.
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dysfunction, leads to adult TDS disorders and, if  so, whether there is a critical period for such an effect. 
In this regard, our findings with regard to the consequences of  DBP-induced androgen deficiency in the 
MPW agree completely with findings from other treatments in which deficiency in androgen action has 
been induced in rats by fetal exposure to androgen receptor antagonists (20, 22, 23, 67–69) or to 5α-reduc-
tase inhibitors (67, 68) during the period now established as the MPW, and such treatments are therapeutic 
antiandrogens in humans. Therefore, we consider our findings conceptually relevant to humans, even if  the 
factors that might induce focal dysgenesis and resulting TDS prove to be different in humans versus rats (70).
In providing animal model validation of  the TDS hypothesis, our results have important human health 
implications, in view of the high, and possibly increasing, prevalence of  TDS disorders in young men (6). 
Induction of  focal testicular dysgenesis, and consequent increased risk of  TDS, can have multiple potential 
causes, ranging from genetic to environmental/lifestyle exposures (3, 6, 9, 51), although the precise causal fac-
tors remain largely unknown. The present studies provide an important step forward in basic understanding 
by highlighting the key importance of  androgen deficiency in the MPW as the underlying mechanistic cause 
of  later TDS disorders and associated reduction in AGD in rats. As there is already a substantial body of  
similar association data in human males (Table 1), it is reasonable to propose that an MPW exists in humans, 
so that studies to identify potential causes of  TDS disorders should focus on the presumptive MPW (~8–14 
weeks’ gestation). While such studies have several inherent limitations, the measurement of  AGD in newborn 
offspring, as an indicator of  androgen exposure within the presumptive MPW, will play an important role, 
even if  interindividual variation may restrict its usefulness to population-based studies (11, 25, 36).
Methods
Human testis tissue. The tissue specimens were fixed overnight in 4% buffered formalin or modified Stieve’s 
fixative. The focus of  the present studies was on men classed as having TDS, and, as the most definitive 
example of  TDS is men diagnosed with TGCC or its preinvasive stage GCNIS (6, 9), the latter group 
was the present focus. For assessment of  preinvasive TGCC, fragments of  orchiectomy specimens with 
GCNIS, (n = 10) were used. All samples were assessed by an experienced pathologist using a panel of  
Figure 10. Suggested revision of the testicular dysgenesis syndrome hypothesis, based on incorporation of findings from the present study. GCNIS, 
germ cell neoplasia in situ.
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immunohistochemical markers to characterize the presence of  preinvasive GCNIS cells. It is emphasized 
that this group of  men is highly selective but constitutes the group of  men on which the original TDS 
hypothesis was founded (6). Access to control “normal” human testis tissue from young adult men com-
parable in age to the GCNIS group is limited for ethical reasons. We used two groups of  samples as con-
trols. The first group (n = 8) comprised biopsies obtained from the “normal” testis of  men who had been 
diagnosed with TGCC in the contralateral testis. In Denmark, all such men diagnosed with TGCC are 
routinely offered a biopsy of  the contralateral testis to determine if  GCNIS is present (71); we used biop-
sies that were negative for GCNIS. The second group (n = 4) comprised men with symptoms of  testicular 
pain but no evidence for any testicular abnormality after orchiectomy.
Animals and treatments. Wistar rats (Harlan) were housed for a minimum of 2 weeks prior to use in experi-
mental studies and had free access to sterile water and a soy-free breeding diet [RM3(E); SDS]. Housing con-
ditions were: lights, 07:00–19:00 hours; temperature, 19°C–21°C; humidity, 45%–65%; and GOLD shavings 
and LITASPEN standard bedding (SPPS). Time-mated females were allocated randomly to receive vehicle 
control treatment or 750 mg/kg DBP (Sigma-Aldrich; 99% pure according to the supplier) in 1 ml/kg corn oil 
daily by oral gavage. The dose of  DBP was chosen as it induces a high incidence of  focal dysgenesis as well 
as profoundly suppressing testosterone production by fetal Leydig cells (40). Three DBP treatment groups 
were used in this study: DBP-FW (E13.5–E21.5), DBP-MPW (E15.5–E18.5), and DBP-LW (E19.5–E21.5). 
All treatments were administered between 09:00–10:30 hours in a single animal facility at the University of  
Edinburgh. No generalized adverse effects of  the DBP treatments were observed in exposed females, and 
litter size and sex ratio were unaffected by treatment. Male fetuses were collected at E17.5 (within the MPW), 
E21.5 (end of  LW), or at Pnd 4, 10, 15, 25, or 90 (adulthood). Animal numbers/litters used varied between 
experiments but always involved at least 3 litters and usually more than 5; for studies of  the adult phenotype 
of  DBP-MPW offspring, 11 litters were used. Pregnant dams were killed by CO2 inhalation followed by cer-
vical dislocation. Fetuses were removed, decapitated, and placed in ice-cold PBS (Sigma-Aldrich). Postnatal 
animals were housed with their natural mothers from birth until weaning or in cages with a maximum of 6 
animals after weaning and were killed by cervical dislocation. Fetal testes were microdissected and fixed in 
Bouin’s fixative for 1 hour, while postnatal testes were fixed in Bouin’s fixative for 3 hours (Pnd 4–25) or 6 
hours (adults) and then transferred to 70% (v/v) ethanol before processing into paraffin blocks by standard 
procedures. Fetal testes used for ITT measurements were snap frozen on dry ice.
Adult reproductive phenotype analysis. Bodyweight was measured and then AGD was measured using dig-
ital callipers (Faithfull Tools). Animals were then subjected to a thorough inspection to determine testicular 
descent and the normality of  the penis. Hypospadias was classified as mild (glanular), moderate, or severe 
(20–22); severe cases were all perineal and included exposure of  the penile os bone. The penis was then 
carefully dissected out, its length was determined using digital callipers, and it was weighed (20–23). Initial 
classification of  cryptorchidism was based on the absence of  one or both testes from the scrotum and an 
inability to manipulate the relevant testis into the scrotum. This preliminary diagnosis was confirmed after 
opening of  the abdomen, when the position of  cryptorchid testes was further defined as high abdominal 
(located adjacent to the kidney) or mid to lower abdominal. The presence or absence of  the gubernacular 
ligament was recorded and, if  present, whether it was normal and short or thin and abnormally elongated 
(>5 times normal). Some high scrotal testes were classified as inguinal when the gubernaculum was found 
to be absent/elongated, as it was considered that these testes could not be consistently anchored in the 
scrotum; these testes were always intermediate in size between normal scrotal testes and fully cryptorchid 
testes. The testes and prostate were dissected out and weighed for each animal, and both testes were fixed 
in Bouin’s as described above.
Triple immunofluorescence for SMA, 3β-HSD, and SOX-9 in rats. To visualize focal dysgenesis and ectopic 
Sertoli cells, specific antibodies were used for coimmunolocalization of  3β-HSD (Leydig cell marker; San-
ta Cruz, catalog SC-30820), SOX-9 (Sertoli cell marker; Chemicon International, catalog AB5535), and 
α-SMA (peritubular myoid cell marker; Sigma-Aldrich, catalog A2547). Slides were washed in between all 
incubation steps in TBS (3 times for 5 minutes each), and all incubations were carried out in a humidity 
box (Fisher Scientific). Sections were dewaxed and rehydrated using standard procedures, followed by a 
peroxidase block in 3% (v/v) H2O2 in methanol for 30 minutes. Next, the sections were blocked in normal 
chicken serum (NCS; Biosera) diluted 1:5 in TBS containing 5% (w/v) BSA (NCS/TBS/BSA), followed by 
incubation with anti–SOX-9 antibody diluted 1:5,000 in NCS/TBS/BSA overnight at 4°C. The next day, 
sections were incubated with peroxidase-conjugated chicken anti-rabbit secondary antibody (Santa Cruz, 
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catalog SC-2963), diluted 1:200 in NCS/TBS/BSA for 30 minutes at room temperature, followed by incu-
bation with Tyr-Cy3 (Perkin Elmer-TSA-Plus Cyanine3 System; Perkin Elmer Life Sciences) according to 
the manufacturer’s instructions. Before the next primary antibody dilution was added, the sections were 
subjected to antigen retrieval by boiling in a pressure cooker in 0.01 mol/l citrate buffer (pH 6.0) for 5 min-
utes, before being left to cool for 20 minutes. This was followed by another block in NCS/TBS/BSA and 
overnight incubation at 4°C with anti–3β-HSD antibody diluted 1:6,000 in NCS/TBS/BSA. On the third 
day, slides were incubated with peroxidase-conjugated chicken anti-goat secondary antibody (Santa Cruz, 
catalog SC-2961) diluted 1:200 in NCS/TBS/BSA for 30 minutes at room temperature, followed by incuba-
tion with Tyr-fl (Perkin Elmer-TSA-Plus Fluorescein System; Perkin Elmer Life Sciences) according to the 
manufacturer’s instructions. Sections were again blocked against peroxidase in 3% (v/v) H2O2 in TBS plus 
0.01% (v/v) Tween-20 (Sigma-Aldrich) for 20 minutes, followed by blocking in NCS/TBS/BSA and incuba-
tion with anti-SMA antibody diluted 1:10,000 in NCS/TBS/BSA for 1 hour at room temperature. Sections 
were then incubated with peroxidase-conjugated chicken anti-mouse secondary antibody (Santa Cruz, cata-
log SC-2962), diluted 1:200 in NCS/TBS/BSA for 30 minutes at room temperature, followed by incubation 
with Tyr-Cy5 (Perkin Elmer-TSA-Plus Cyanine5 System; Perkin Elmer Life Sciences) according to the man-
ufacturer’s instructions. Finally, slides were mounted with Permafluor (Thermo Scientific), and fluorescent 
images were captured using a Zeiss LSM 710 Axio Observer Z1 confocal laser microscope (Carl Zeiss Ltd).
Identification and quantification of  focal dysgenetic areas in rats. For the purposes of  the present studies, focal 
dysgenetic areas in rats were classified using different criteria in fetal life than postnatally, as explained in 
Results. Thus, in E17.5 and E21.5 fetal testes, identification was based on the number of  ectopic Sertoli 
cells, which were determined as follows. Testes from the different age and treatment groups (n = 3–15 from 
3–5 litters per treatment group) were serial sectioned, and 3 sections were chosen, corresponding to approx-
imately 25%, 50%, and 75% intervals through the serially sectioned testis; these were triple immunostained 
for α-SMA, 3β-HSD, and SOX-9, as above. Whole testis confocal scanned images were recorded and used to 
count all SOX-9–positive (Sertoli) cells per testis cross section that were located in the interstitium and outside 
of  seminiferous cords (ectopic Sertoli cells), and the total number per testis was determined. In early postnatal 
and adult rat testes, focal dysgenetic areas were visualized by double immunostaining for α- SMA (Sigma-Al-
drich) and 3β-HSD (Santa Cruz) as described elsewhere (72) to delineate seminiferous cords/tubules from the 
interstitial compartment. Any focal area in the testis that exhibited grossly misshapen seminiferous tubules 
was classed as a focal dysgenetic area; these varied considerably in shape and size but were generally more 
extensive and bizarre in cryptorchid than in noncryptorchid testes (see Supplemental Figure 1). All focal dys-
genetic areas occurred in central regions of  the testis. To determine the percentage volume of  focal dysgenetic 
areas per testis, two complete cross sections per testis were analyzed using a Zeiss Axio-Imager microscope 
(Carl Zeiss Ltd.) fitted with a Hitachi HVC20 camera (Hitachi Denshi Europe) and a Prior automatic stage 
(Prior Scientific Instruments Ltd.). Image-Pro 6.2 with Stereologer plug-in software (Mag-Worldwide) was 
used to draw around the complete testis cross section and focal dysgenetic areas to determine their areas; 
percentage focal dysgenesis was then computed as the ratio of  the latter to the former × 100.
Identification of  tubules with incomplete spermatogenesis or SCO in rats. To visualize germ cells and thus 
to identify SCO tubules and tubules with incomplete spermatogenesis in adult rat testes, sections were 
immunostained with an antibody to detect the germ cell marker DAZL (gift from H. Cooke, University of  
Edinburgh; 1:1,000), using standard immunohistochemistry techniques as described elsewhere (73). Two 
complete cross sections of  each adult testis were then systematically evaluated by a person blinded to the 
treatment group who identified any tubules with incomplete spermatogenesis (i.e., tubules lacking specific 
germ cell types that should be present, tubules with clearly reduced germ cell numbers, or tubules with no 
germ cells [SCO]); note that SCO tubules located at the testis periphery were ignored, as these are likely 
to be a normal part of  the rete testis. Any animal exhibiting any tubule with incomplete spermatogenesis 
or SCO was classified as having this dysgenetic feature, although it is emphasized that where such tubules 
were present they were usually quite numerous.
Identification and quantification of  focal dysgenetic features in the human adult testis. Using methods similar to those 
in the rat above, triple immunostaining for SOX-9 (Sertoli cells; Chemicon, catalog AB5535, 1:200), CYP11a1 
(Leydig cells; Sigma-Aldrich, 1:50), and VASA (germ cells; Abcam, catalog AB13840, 1:80) was used to delin-
eate cell types for analysis, using methods and antibodies validated previously (47, 48, 55, 74). Sections were 
blocked using 20% normal goat serum (v/v) (Biosera) and 5% BSA (w/v) (Sigma-Aldrich) in TBS. Second-
ary antibodies were diluted 1:500 in sera, and slides were incubated for 30 minutes with Streptavidin-alkaline 
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phosphatase (Vector) at 1:200 in TBS. Fast blue and red were used for protein detection (Perma Blue/Red, 
Diagnostic BioSystems), followed by antigen retrieval for 2.5 minutes on medium heat. Sections were reblocked 
in serum/TBS/BSA as above before application of (second) primary antibody, followed by repetition of the 
above. Streptavidin-horseradish peroxidase (Dako) at 1:500 in TBS was used for detection of 3,3-diaminobenzi-
dine tetrahydrochloride (Dako). Slides were mounted with Permafluor (Thermo Scientific). Each immunohis-
tochemistry run included negative controls for each primary antibody. Immunostained testis cross sections were 
evaluated in a similar fashion to the rat, as described above. Each testis cross section was characterized for (a) 
focal areas of dysgenesis, (b) normality or not of spermatogenesis per tubule, and (c) SCO tubules (SOX9-only 
staining and absence of GC morphology), using approaches comparable to those described above for the rat. 
Where dysgenetic features (b and c) were observed, their relative occurrence was determined in relation to the 
number of tubules with normal spermatogenesis in the same testis sample; the number of seminiferous tubules 
evaluated ranged from 94 to 221 in normal controls and 111 to 390 in preinvasive GCNIS samples.
Rat hormone measurements. Testosterone levels in plasma from adult rats were subjected to organic extraction 
and subsequent hormone measurement by an ELISA assay adapted from an earlier, established radioimmuno-
assay using methods outlined previously (75, 76); the same assay was used to measure fetal ITT, as described 
by Mahood et al. (50). This assay has been used extensively for the robust measurement of testosterone in 
biological media from rats (75), mice (77), monkeys (76), and sheep (78) of both sexes; plasma samples from 
castrate adult rats show values below the assay limit of detection (40 pg/sample for the current studies). Plasma 
LH was measured by an established radioimmunoassay as outlined previously (79). All samples from each 
experiment were run in a single assay, and the within-assay coefficients of variation were all <10%.
Statistics. Values are expressed as mean ± SEM. Comparison of  treatment effects used 1-way ANOVA, 
followed by Bonferroni correction when multiple treatment groups were being compared, or 2-tailed Stu-
dent’s t test for comparisons between two groups. Incidence data were analyzed using Fisher’s exact test, 
followed by Bonferroni correction when multiple endpoints were being evaluated. Linear regression analy-
sis was used to determine the relationship between AGD and reproductive organ and hormone parameters, 
but second order polynomial (quadratic) regression, with statistical significance evaluated via Spearman 
correlation, was used to evaluate the relationship between AGD and focal dysgenesis. Data were log trans-
formed prior to analysis if  they were not normally distributed, as was the case for plasma testosterone 
levels. The analyses used GraphPad Prism (version 6; GraphPad Software Inc.). A P value of  less than 0.05 
was considered significant. The presented data used each animal as the unit, rather than the litter, because 
the basis of  the present studies was to evaluate the interrelationships between treatment effects on AGD, 
ITT, plasma testosterone and LH, dysgenesis, and adult phenotype at the individual level.
Study approval. The animals used in this study were treated humanely and according to the Animal 
(Scientific Procedures) Act 1986 (http://www.legislation.gov.uk/ukpga/1986/14/contents) under project 
license (PPL 60/4564) approval by the UK Home Office. Studies were conducted following review by the 
University of  Edinburgh Animal Research Ethics Committee.
Adult human testicular biopsies or testis tissue from orchiectomy were obtained from the Western 
General Hospital, Edinburgh, and from samples stored in the tissue archives of  Copenhagen University 
Hospital. Ethical approval was obtained by the East of  Scotland Research Ethics Committee (REC refer-
ence - 15/ES/0094) and the regional Committee for Medical Research Ethics in Denmark (permit numbers 
KF-01 26 5848 and H-1-2012- 007).
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